Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer’s, Diabetes, Arthritis and Other Diseases)


January 1, 2012
160 Pages - SKU: KLI6490034
License type:
The World Market for Pain Management Drugs and Devices
5/20/2013 | published by: Kalorama Information
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and  |  read more...
$3,500.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
5/15/2013 | published by: GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players”. The report is a vital source of up-to-date information with  |  read more...
$2,995.00
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
5/15/2013 | published by: GlobalData
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is  |  read more...
$3,495.00
Global Cardiac Bio Implant Devices (Implantable Cardioverter Defibrillators, Implantable Cardiac Pacemakers, Heart Valve, Coronary Stent, Peripheral Stent, Ventricular Assist Device) Market Forecast, Clinical Trials, M&A
5/20/2013 | published by: Renub Research
The cardiac implant medical device market is forecasted to grow in single digit percent per year during 2010-2017 and is likely to exceed US$ 27 Billion by 2017. Growth in this sector is anticipated to  |  read more...
$1,600.00
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease
5/14/2013 | published by: GBI Research
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease Summary GBI Research’s report “Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI)  |  read more...
$3,500.00
EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022
5/15/2013 | published by: GlobalData
EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022 Summary Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani  |  read more...
$3,995.00